(Q43034871)

12 November 2017

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

2

Espen Melum

1 reference

12 November 2017

Amir Moghaddam

1

1 reference

12 November 2017

Nils Reinton

3

1 reference

12 November 2017

Helmer Ring-Larsen

4

1 reference

12 November 2017

Hans Verbaan

5

1 reference

12 November 2017

Kristian Bjøro

6

1 reference

12 November 2017

Olav Dalgard

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

12 November 2017

1 reference

12 November 2017

53

1 reference

12 November 2017

3

1 reference

12 November 2017

746-754

1 reference

12 November 2017

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

21 January 2018

1 reference

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

21 January 2018

1 reference

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

21 January 2018

1 reference

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

Multiple displacement amplification to create a long-lasting source of DNA for genetic studies

21 January 2018

1 reference

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.24154

1 reference

12 November 2017

1 reference